CDKN2B-AS1 and breast carcinoma: Towards this direction, one recent study using a small cohort has demonstrated that a three‐lncRNA signature, including ANRIL, HIF1A‐AS2 and UCA1, can serve as diagnostic markers for differentiating between triple‐negative and non‐triple‐negative breast cancer.51 Evidently, further systematic and multicenter studies of larger independent samples are urgently needed to develop the possible clinical applications of circulating lncRNAs in patients with breast cancer.